All In MedTech

FDA Clearance Tracker · P970004-S064

INTERSTIM THERAPY FOR URINARY CONTROL

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 30, 2009 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 30, 2009

Approved

Time to decision

178 days

Received Nov 3, 2008. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P970004-S064
Device name
INTERSTIM THERAPY FOR URINARY CONTROL
Applicant location
Minneapolis, MN
Received
Nov 3, 2008
Decided
Apr 30, 2009
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P970004

Device type

Device class
Class III
Regulation
21 CFR 876.5270

Every decision under product code EZW

FDA's approval statement

As written in FDA's record.

APPROVAL FOR CLARIFYING LABELING MODIFICATIONS AND EXTENSION OF THE TINED LEAD TEST IMPLANTATION TO 14 DAYS.

Source documents

Other decisions for Medtronic Neuromodulation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.